Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China


CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals

See the original post:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

Related Posts